Biopharmx Corp (NYSEAMERICAN:BPMX) gapped down before the market opened on Friday after an insider sold shares in the company. The stock had previously closed at $0.27, but opened at $0.30. Biopharmx shares last traded at $0.31, with a volume of 11530347 shares trading hands.
Specifically, major shareholder Vivo Capital Viii, Llc sold 2,000,000 shares of Biopharmx stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $0.36, for a total value of $720,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Separately, Maxim Group reiterated a “buy” rating and issued a $1.50 price objective on shares of Biopharmx in a research report on Friday, December 8th.
Biopharmx (NYSEAMERICAN:BPMX) last released its earnings results on Thursday, December 7th. The biotechnology company reported ($0.05) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.05). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million.
An institutional investor recently bought a new position in Biopharmx stock. Armistice Capital LLC acquired a new position in Biopharmx Corp (NYSEAMERICAN:BPMX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 3,470,000 shares of the biotechnology company’s stock, valued at approximately $382,000. Armistice Capital LLC owned about 2.72% of Biopharmx at the end of the most recent reporting period.
ILLEGAL ACTIVITY WARNING: “Biopharmx (BPMX) Shares Gap Down on Insider Selling” was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://weekherald.com/2018/03/11/biopharmx-bpmx-shares-gap-down-on-insider-selling.html.
Biopharmx Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.